Learn About Macular Corneal Dystrophy Type 1

What is the definition of Macular Corneal Dystrophy Type 1?
Macular corneal dystrophy (MCD-1) type 1 is a rare, severe eye disease characterized by a cloudy, irregular covering over the cornea (outer covering of the eye), also known as a stromal corneal dystrophy.
Save information for later
Sign Up
What are the symptoms of Macular Corneal Dystrophy Type 1?
Symptoms of macular corneal dystrophy type 1 include a progressive whitish opacity that clouds the covering of the eye (cornea) which eventually causes severe visual impairment.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Macular Corneal Dystrophy Type 1?
Treatment for macular corneal dystrophy type 1 includes corneal grafting or corneal transplantation.
Who are the top Macular Corneal Dystrophy Type 1 Local Doctors?
CC
Dr. Claiborne M. Callahan
Ophthalmology
Experienced
Highly rated in
2
conditions
Ophthalmology

Inova

Callahan Eye

20 Davis Ave Sw, 
Leesburg, VA 
 5.9 mi

Claiborne Callahan is an Ophthalmologist in Leesburg, Virginia. Dr. Callahan has been practicing medicine for over 23 years and is rated as an Experienced doctor by MediFind in the treatment of Macular Corneal Dystrophy Type 1. She is also highly rated in 2 other conditions, according to our data. Her top areas of expertise are Blepharitis, Dry Eye Syndrome, Cataract, and Macular Corneal Dystrophy Type 1. Dr. Callahan is currently accepting new patients.

SS
Dr. Soo Y. Shin
Ophthalmology
Experienced
Highly rated in
0
conditions
Ophthalmology

VA Capitol Health Care Network

Virginia Eye Center PC

19441 Golf Vista Plaza, 
Leesburg, VA 
 2.2 mi

Soo Shin is an Ophthalmologist in Leesburg, Virginia. Dr. Shin has been practicing medicine for over 31 years and is rated as an Experienced doctor by MediFind in the treatment of Macular Corneal Dystrophy Type 1. Her top areas of expertise are Cataract, Traumatic Brain Injury, Macular Corneal Dystrophy Type 1, Corneal Dystrophy and Perceptive Deafness, and Cataract Removal. Dr. Shin is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn more
MS
Dr. Mehrine S. Shaikh
Ophthalmology
Experienced
Highly rated in
0
conditions
Ophthalmology

Inova

Lansdowne

19415 Deerfield Ave, 
Lansdowne, VA 
 2.3 mi

Mehrine Shaikh is an Ophthalmologist in Lansdowne, Virginia. Dr. Shaikh has been practicing medicine for over 15 years and is rated as an Experienced doctor by MediFind in the treatment of Macular Corneal Dystrophy Type 1. Her top areas of expertise are Blepharitis, Dry Eye Syndrome, Choroid Plexus Carcinoma, and Uveitis. Dr. Shaikh is currently accepting new patients.

View All Doctors
What are the latest Macular Corneal Dystrophy Type 1 Clinical Trials?
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy
Enrollment Status: Not yet recruiting
Publish Date: April 03, 2023
Intervention Type: Drug
Study Phase: Phase 3

Summary: A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) - PHANTOM Study
Enrollment Status: Recruiting
Publish Date: February 02, 2023
Intervention Type: Drug
Study Phase: Phase 2

Summary: This is a Phase IIa study to assess efficacy and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD). This study will consist of a Screening Period of up to 15 days and an 18-month Double-Masked Treatment Period.

View All Clinical Trials
What are the Latest Advances for Macular Corneal Dystrophy Type 1?
Should Patients with Kearns-Sayre Syndrome and Corneal Endothelial Failure Be Genotyped for a TCF4 Trinucleotide Repeat, Commonly Associated with Fuchs Endothelial Corneal Dystrophy?
Journal: Genes
Published: December 24, 2021
An Arg124Cys mutation in transforming growth factor β-induced gene associated with lattice corneal dystrophy type I in a Chinese pedigree.
Journal: Indian journal of ophthalmology
Published: December 23, 2021
Tired of the same old research?
Check Latest Advances
Descemetorhexis Without Endothelial Keratoplasty in Fuchs Endothelial Corneal Dystrophy: A Systematic Review and Meta-Analysis.
Condition: Fuchs Endothelial Corneal Dystrophy
Journal: Cornea
Treatment Used: Descemetorhexis Without Endothelial Keratoplasty
Number of Patients: 118
Published: December 08, 2021
View All Latest Advances